BDD Scintigraphy

BDD Scintigraphy
Product Description

Gamma scintigraphy is a powerful and versatile technology used to investigate the in-vivo performance of your drug or product. This non-invasive imaging technique allows us to follow the fate of the dosage form and administering it to a volunteer or patient. Not limited to just oral dosage forms, gamma scintigraphy can be used to image formulation behaviour in the lungs, eyes, nose, oesophagus or any other site of administration of your product. PK analysis can be coupled with scintigraphy to give a complete picture of your products behaviour. We are market leaders in gamma scintigraphy with a proven track record and a global client base.
Scintigraphy is a powerful, fast and incredibly effective tool providing a much clearer picture than PK data alone offers. The information that you get on the in vivo performance of your formulation combined with our expertise allows you to shape your formulation development strategy, reducing costs and time to market. Scintigraphic data can also be used to support drug delivery claims, for marketing or regulatory purposes.

BDD Pharma Ltd

  • GB
  • 2016
    On CPHI since
  • 50 - 99
    Employees
Company types
CMO/CDMO
Contract Service
Specifications
  • Selling Points
    Product Features
  • Supplied from
    United Kingdom

BDD Pharma Ltd

  • GB
  • 2016
    On CPHI since
  • 50 - 99
    Employees
Company types
CMO/CDMO
Contract Service

More Products from BDD Pharma Ltd (2)

  • BDD Swift - adaptive clinical studies

    Product BDD Swift - adaptive clinical studies

    •SWIFT accelerates evaluation and optimisation of product performance using in vivo clinical data to direct formulation design in real time.
    •SWIFT studies enable you to make decisions on formulation changes based on emerging clinical data. • This integration of formulation development, GMP manufactu...
  • OralogiK™ - Controlled release technology

    Product OralogiK™ - Controlled release technology

    BDD has developed an erosion based controlled release technology that provides unrivaled control of drug release at a pre-defined time with no release of drug prior to the pulse. The technology is an erodible barrier layer that is wrapped around a drug containing core to give a tablet in tablet dose form. ...

BDD Pharma Ltd resources (1)

  • Video Oralogik - A New Approach to Complex Oral Drug Delivery Profiles

    BDD has developed an erosion based controlled release technology that provides unrivalled control of drug release at a pre-defined time with no release of drug prior to the pulse. The technology is an erodible barrier layer that is wrapped around a drug containing core to give a tablet in tablet dose form. The barrier layer is designed to erode at a controlled rate until eventually the drug is released from the core tablet, and the length of the delay period can be tailored between 2 and 8 hours by simply changing excipient ratios.

    The barrier layer works independently of the core so can be applied to almost any drug where there is a therapeutic need, with minimal development. The release can be sustained or pulsed release giving unparalleled versatility.

    The OralogiK barrier layer can be readily film coated, allowing addition of an immediate release dose which can be the same or different to the drug in the core tablet